Protective effect of sulodexide on podocyte injury in adriamycin nephropathy rats

Journal of Huazhong University of Science and Technology - Medical Science

Volumn 29, Issue 6, 2009, Pages 715-719

  Chen, Shan ^a   Fang, Zhan ^a   Zhu, Zhonghua ^a   Deng, Anguo ^a   Liu, Jianshe ^a   Zhang, Chun ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Adriamycin nephropathy; Heparanase; Podocyte; Sulodexide

Indexed keywords

BETA GLUCURONIDASE; CD2 ASSOCIATED PROTEIN; CD2-ASSOCIATED PROTEIN; CYTOSKELETON PROTEIN; DESMIN; DOXORUBICIN; GLYCOSAMINOGLYCAN; HEPARANASE; MESSENGER RNA; PROTECTIVE AGENT; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SULODEXIDE;

ANIMAL; ARTICLE; CHEMICALLY INDUCED DISORDER; DOWN REGULATION; DRUG EFFECT; GENETICS; GLOMERULUS; KIDNEY DISEASE; MALE; METABOLISM; PATHOLOGY; PODOCYTE; RANDOMIZATION; RAT; SPRAGUE DAWLEY RAT;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CYTOSKELETAL PROTEINS; DESMIN; DOWN-REGULATION; DOXORUBICIN; GLUCURONIDASE; GLYCOSAMINOGLYCANS; KIDNEY DISEASES; KIDNEY GLOMERULUS; MALE; PODOCYTES; PROTECTIVE AGENTS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER;

EID: 77149170059     PISSN: 16720733     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11596-009-0608-0     Document Type: Article

References (25)

1. S.J. Shankland 2006 The podocyte's response to injury: role in proteinuria and glomerulosclerosis Kidney Int 69 12 2131 2147 10.1038/sj.ki.5000410 1:CAS:528:DC%2BD28XlsVert70%3D 16688120 (Pubitemid 43882099)
2. J. Patrakka K. Tryggvason 2009 New insights into the role of podocytes in proteinuria Nat Rev Nephrol 5 8 463 468 10.1038/nrneph.2009.108 1:CAS:528:DC%2BD1MXpsVKgsLg%3D 19581907
3. T.J. Wijnhoven J.F. Lensen A.L. Rops, et al. 2007 Anti-proteinuric effects of glycosaminoglycan-based drugs Curr Opin Mol Ther 9 4 364 377 1:CAS:528:DC%2BD2sXhtFalsbnF 17694449
4. S. Coccheri G. Scondotto H. Agnelli 2002 Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial J Am Soc Nephrol 13 6 1615 1625 10.1097/01.ASN.0000014254.87188.E5 (Pubitemid 34579250)
5. E.J. Lewis X. Xu 2008 Abnormal glomerular permeability characteristics in diabetic nephropathy: implications for the therapeutic use of low-molecular weight heparin Diabetes Care 31 2 202 207 10.2337/dc08-s251
6. E. Vilayur D.C. Harris 2009 Emerging therapies for chronic kidney disease: what is their role? Nat Rev Nephrol 5 7 375 383 10.1038/nrneph.2009.76 1:CAS:528:DC%2BD1MXnslGrurs%3D 19455178
7. G. Gheorghe S. Adalbert R. Marius 2001 The effects of the therapy with natural glycosaminoglycans (sulodexide) on proteinuria in different types of glomerulorphritis Facta Universitatis Series: Medicine and Biology 8 1 26 30
8. R.J. Smith J. Alexander P.N. Barlow, et al. 2007 New approaches to the treatment of dense deposit disease J Am Soc Nephrol 18 9 2447 2456 10.1681/ASN.2007030356 1:CAS:528:DC%2BD2sXhtV2mur3L 17675665 (Pubitemid 47378860)
9. Y. Xing J. Ding Q. Fan, et al. 2006 Diversities of podocyte molecular changes induced by different antiproteinuria drugs Exp Biol Med 231 5 585 593 1:CAS:528:DC%2BD28XktlCqsLw%3D
10. B. Daniels R.J. Linhardt F. Zhang, et al. 2006 In vivo antithrombotic synergy of oral heparin and arginine: endothelial thromboresistance without changes in coagulation parameters Thromb Haemost 95 5 865 872 1:CAS:528:DC%2BD28Xlt1Wgur4%3D 16676079
11. M. Ceol A. Nerlich B. Baggio Anglani, et al. 1996 Increased glomerular alpha 1 (IV) collagen expression and deposition in long-term diabetic rats is prevented by chronic glycosaminoglycan treatment Lab Invest 74 2 484 495 1:CAS:528:DyaK28Xit12lt7s%3D 8780166
12. M. Ciszewicz A. Polubinska A. Antoniewicz, et al. 2009 Sulodexide suppresses inflammation in human endothelial cells and prevents glucose cytotoxicity Transl Res 153 3 118 123 10.1016/j.trsl.2008.12.007 1:CAS:528:DC%2BD1MXhvFGkur8%3D 19218094
13. M. Ceol G. Gambaro U. Sauer, et al. 2000 Glycosaminoglycan therapy prevents TGF-beta1 overexpression and pathologic changes in renal tissue of long-term diabetic rats J Am Soc Nephrol 11 12 2324 2336 1:CAS:528: DC%2BD3cXptVagsbw%3D 11095655
14. K. Asanuma E. Yanagida-Asanuma M. Takagi 2007 The role of podocytes in proteinuria Nephrology 12 3 15 20 10.1111/j.1440-1797.2007.00876.x (Pubitemid 350077387)
15. J.K. Deegens H.B. Dijkman G.F. Borm, et al. 2008 Podocyte foot process effacement as a diagnostic tool in focal segmental glomerulosclerosis Kidney Int 74 12 1568 1576 10.1038/ki.2008.413 18813290
16. J. Zou E. Yaoita Y. Watanabe 2006 Upregulation of nestin, vimentin, and desmin in rat podocytes in response to injury Virchows Arch 448 4 485 492 10.1007/s00428-005-0134-9 1:CAS:528:DC%2BD28XjtFamsL0%3D 16418842
17. C.X. Zheng Z.H. Chen C.H. Zeng, et al. 2008 Triptolide protects podocytes from puromycin aminonucleoside induced injury in vivo and in vitro Kidney Int 74 5 596 612 10.1038/ki.2008.203 1:CAS:528:DC%2BD1cXpvVaiur8%3D 18509322
18. P.Y. Chuang J.C. He 2009 Signaling in regulation of podocyte phenotypes Nephron Physiol 111 2 9 15 10.1159/000191075
19. J.M. Kim H. Wu G. Green, et al. 2003 CD2-associated protein haploinsufficiency is linked to glomerular disease susceptibility Science 300 5623 1298 1300 10.1126/science.1081068 1:CAS:528:DC%2BD3sXktFGkt7s%3D 12764198 (Pubitemid 36618242)
20. T.B. Huber B. Hartleben J. Kim, et al. 2003 Nephrin and CD2AP associate with phosphoinositide 3-OH kinase and stimulate AKT-dependent signaling Mol Cell Biol 23 14 4917 4928 10.1128/MCB.23.14.4917-4928.2003 1:CAS:528: DC%2BD3sXltlelu78%3D 12832477 (Pubitemid 36793337)
21. C. Zhang H.J. Jiang Y. Chang, et al. 2009 Downregulation of CD2-associated protein impaired the physiological functions of podocytes Cell Biol Int 33 6 632 639 10.1016/j.cellbi.2009.02.017 1:CAS:528: DC%2BD1MXms1Ojs7g%3D 19306938
22. V. Levidiotis C. Freeman C. Tikellis, et al. 2004 Heparanase is involved in the pathogenesis of proteinuria as a result of glomerulonephritis J Am Soc Nephrol 15 1 68 78 10.1097/01.ASN.0000103229.25389.40 1:CAS:528: DC%2BD2cXhs1ahtg%3D%3D 14694159 (Pubitemid 38020699)
23. V. Levidiotis J. Kanellis F.L. Ierino, et al. 2001 Increased expression of heparanase in puromycin aminonucleoside nephrosis Kidney Int 60 4 1287 1296 10.1046/j.1523-1755.2001.00934.x 1:CAS:528:DC%2BD3MXnsFSjtbY%3D 11576343 (Pubitemid 32960024)
24. M.J. van den Hoven A.L. Rops M.A. Bakker 2006 Increased expression of heparanase in overt diabetic nephropathy Kidney Int 70 12 2100 2108 17051139
25. M.J. van den Hoven A.L. Rops I. Vlodavsky 2007 Heparanase in glomerular diseases Kidney Int 72 5 543 548 10.1038/sj.ki.5002337 17519955 (Pubitemid 47312787)